Autres langues BioRestorative Therapies, Inc.

Actions

BRTX

US0906556065

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 24/07/2026			Varia. 5j.	Varia. 1 janv.
0,2900 ^USD	-7,17%		-13,20%	-75,32%

16/07	BioRestorative Therapies, Inc. annonce un changement de direction, effectif au 13 juillet 2026	CI
16/07	BioRestorative Therapies, Inc. annonce des changements au sein de son conseil d'administration et de sa direction	CI

Autres langues

16/07	BioRestorative Therapies, Inc. Announces CEO Changes, Effective July 13, 2026
16/07	BioRestorative Therapies, Inc. Announces CFO Changes, Effective July 13, 2026
16/07	Biorestorative Therapies, Inc. Announces Board and Management Changes
25/06	BioRestorative Therapies Announces Completion of BRTX-100 Phase 2 Manufacturing, Highlighting Integrated Regenerative Biologics Platform
25/06	BioRestorative Therapies Completes Manufacturing for BRTX-100 Phase 2 Clinical Trial
18/06	BioRestorative Therapies Strengthens Leadership with Appointment of Healthcare Executive Zachary Smith as Vice President of Biocosmeceuticals Division to Accelerate Commercial Expansion and Strategic Growth
16/06	BioRestorative Therapies, Inc.'s Equity Buyback announced on August 12, 2025, has expired.
12/06	BioRestorative Therapies, Inc. Announces Board and Committee Changes
12/06	BioRestorative Therapies, Inc. Enters Into $1,000,000 Revolving Loan Agreement With Bowery Group LLC
27/05	Kaos Capital acquires 4.9% stake in BioRestorative Therapies
27/05	Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX)
26/05	BioRestorative Completes Dosing in Phase 2 Trial of BRTX-100 to Treat Chronic Lumbar Disc Disease; Shares Rise
26/05	Biorestorative Therapies says topline phase 2 data for BRTX-100 expected in Q2 2027
26/05	BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data
26/05	BioRestorative Therapies, Inc. Completes Phase 2 Dosing Of BRTX-100 And Advances Lead Regenerative Spine Program Toward 2027 Topline Data
15/05	9,046,242 Common Stock of BioRestorative Therapies, Inc. are subject to a Lock-Up Agreement Ending on 15-MAY-2026.
15/05	Certain Series B Preferred Stock of BioRestorative Therapies, Inc. are subject to a Lock-Up Agreement Ending on 15-MAY-2026.
15/05	Certain Warrants of BioRestorative Therapies, Inc. are subject to a Lock-Up Agreement Ending on 15-MAY-2026.
15/05	Certain Options of BioRestorative Therapies, Inc. are subject to a Lock-Up Agreement Ending on 15-MAY-2026.
14/05	Tranche Update on BioRestorative Therapies, Inc.'s Equity Buyback Plan announced on August 12, 2025.
14/05	BioRestorative Therapies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
13/05	BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticals
13/05	Biorestorative Therapies Presents New Preclinical Data on Source-Specific Exosome Functionality and Commercial Applications in Biocosmeceuticals
07/05	Biorestorative Therapies' BRTX-100 shows sustained pain & functional improvements in chronic lumbar disc disease
07/05	BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease